TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease

Tore Grimstad, Inger Marie Skoie, Jessica Doerner, Kjetil Isaksen, Lars Karlsen, Lars Aabakken, Roald Omdal, Chaim Putterman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) may be involved in the pathogenesis of inflammatory bowel disease. The aim was to investigate if TWEAK may reflect disease activity in inflammatory bowel disease. Materials and methods: In this cohort study, 139 consecutive patients with newly diagnosed and previously untreated inflammatory bowel disease–95 with ulcerative colitis (UC) and 44 with Crohn’s disease (CD)–underwent colonoscopy. Disease activity was assessed by the Mayo score and the Mayo endoscopic score (MES) for UC, or the Simple Endoscopic Score (SES) for CD. Serum C-reactive protein (CRP) and fecal calprotectin were measured in IBD patients, as were plasma TWEAK levels in patients and 85 healthy subjects. Associations between TWEAK levels and disease activity markers were explored. Results: In the total IBD group, the median (interquartile range) TWEAK level was 430 pg/ml (109–6570), in UC 502 pg/ml (109–4547) and in CD patients 352 pg/ml (101–9179), respectively. Healthy subjects had a median (IQR) TWEAK of 307 pg/ml (63–3492). There were no significant differences in TWEAK levels between the total IBD group and healthy control subjects, nor between UC and CD, or between UC/CD and healthy subjects. Furthermore, we found no significant associations between Mayo scores, MES-UC, SES-CD, CRP, and fecal calprotectin with plasma TWEAK levels. Conclusions: Plasma TWEAK levels do not reflect disease activity or the grade of inflammation in patients with newly diagnosed inflammatory bowel disease. NCT01551563.

Original languageEnglish (US)
Pages (from-to)420-424
Number of pages5
JournalScandinavian Journal of Gastroenterology
Volume52
Issue number4
DOIs
StatePublished - Apr 3 2017

Fingerprint

Ulcerative Colitis
Inflammatory Bowel Diseases
Crohn Disease
Healthy Volunteers
Leukocyte L1 Antigen Complex
C-Reactive Protein
Colonoscopy
Blood Proteins
Cohort Studies
Tumor Necrosis Factor-alpha
Apoptosis
Inflammation
Control Groups

Keywords

  • biomarker
  • Crohn’s disease
  • Inflammatory bowel disease
  • TWEAK
  • ulcerative colitis

ASJC Scopus subject areas

  • Medicine(all)
  • Gastroenterology

Cite this

TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease. / Grimstad, Tore; Skoie, Inger Marie; Doerner, Jessica; Isaksen, Kjetil; Karlsen, Lars; Aabakken, Lars; Omdal, Roald; Putterman, Chaim.

In: Scandinavian Journal of Gastroenterology, Vol. 52, No. 4, 03.04.2017, p. 420-424.

Research output: Contribution to journalArticle

Grimstad, T, Skoie, IM, Doerner, J, Isaksen, K, Karlsen, L, Aabakken, L, Omdal, R & Putterman, C 2017, 'TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease', Scandinavian Journal of Gastroenterology, vol. 52, no. 4, pp. 420-424. https://doi.org/10.1080/00365521.2016.1273382
Grimstad, Tore ; Skoie, Inger Marie ; Doerner, Jessica ; Isaksen, Kjetil ; Karlsen, Lars ; Aabakken, Lars ; Omdal, Roald ; Putterman, Chaim. / TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease. In: Scandinavian Journal of Gastroenterology. 2017 ; Vol. 52, No. 4. pp. 420-424.
@article{3e9ff89a3f2c4653b739f29f80f8f3de,
title = "TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease",
abstract = "Objective: Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) may be involved in the pathogenesis of inflammatory bowel disease. The aim was to investigate if TWEAK may reflect disease activity in inflammatory bowel disease. Materials and methods: In this cohort study, 139 consecutive patients with newly diagnosed and previously untreated inflammatory bowel disease–95 with ulcerative colitis (UC) and 44 with Crohn’s disease (CD)–underwent colonoscopy. Disease activity was assessed by the Mayo score and the Mayo endoscopic score (MES) for UC, or the Simple Endoscopic Score (SES) for CD. Serum C-reactive protein (CRP) and fecal calprotectin were measured in IBD patients, as were plasma TWEAK levels in patients and 85 healthy subjects. Associations between TWEAK levels and disease activity markers were explored. Results: In the total IBD group, the median (interquartile range) TWEAK level was 430 pg/ml (109–6570), in UC 502 pg/ml (109–4547) and in CD patients 352 pg/ml (101–9179), respectively. Healthy subjects had a median (IQR) TWEAK of 307 pg/ml (63–3492). There were no significant differences in TWEAK levels between the total IBD group and healthy control subjects, nor between UC and CD, or between UC/CD and healthy subjects. Furthermore, we found no significant associations between Mayo scores, MES-UC, SES-CD, CRP, and fecal calprotectin with plasma TWEAK levels. Conclusions: Plasma TWEAK levels do not reflect disease activity or the grade of inflammation in patients with newly diagnosed inflammatory bowel disease. NCT01551563.",
keywords = "biomarker, Crohn’s disease, Inflammatory bowel disease, TWEAK, ulcerative colitis",
author = "Tore Grimstad and Skoie, {Inger Marie} and Jessica Doerner and Kjetil Isaksen and Lars Karlsen and Lars Aabakken and Roald Omdal and Chaim Putterman",
year = "2017",
month = "4",
day = "3",
doi = "10.1080/00365521.2016.1273382",
language = "English (US)",
volume = "52",
pages = "420--424",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease

AU - Grimstad, Tore

AU - Skoie, Inger Marie

AU - Doerner, Jessica

AU - Isaksen, Kjetil

AU - Karlsen, Lars

AU - Aabakken, Lars

AU - Omdal, Roald

AU - Putterman, Chaim

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Objective: Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) may be involved in the pathogenesis of inflammatory bowel disease. The aim was to investigate if TWEAK may reflect disease activity in inflammatory bowel disease. Materials and methods: In this cohort study, 139 consecutive patients with newly diagnosed and previously untreated inflammatory bowel disease–95 with ulcerative colitis (UC) and 44 with Crohn’s disease (CD)–underwent colonoscopy. Disease activity was assessed by the Mayo score and the Mayo endoscopic score (MES) for UC, or the Simple Endoscopic Score (SES) for CD. Serum C-reactive protein (CRP) and fecal calprotectin were measured in IBD patients, as were plasma TWEAK levels in patients and 85 healthy subjects. Associations between TWEAK levels and disease activity markers were explored. Results: In the total IBD group, the median (interquartile range) TWEAK level was 430 pg/ml (109–6570), in UC 502 pg/ml (109–4547) and in CD patients 352 pg/ml (101–9179), respectively. Healthy subjects had a median (IQR) TWEAK of 307 pg/ml (63–3492). There were no significant differences in TWEAK levels between the total IBD group and healthy control subjects, nor between UC and CD, or between UC/CD and healthy subjects. Furthermore, we found no significant associations between Mayo scores, MES-UC, SES-CD, CRP, and fecal calprotectin with plasma TWEAK levels. Conclusions: Plasma TWEAK levels do not reflect disease activity or the grade of inflammation in patients with newly diagnosed inflammatory bowel disease. NCT01551563.

AB - Objective: Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) may be involved in the pathogenesis of inflammatory bowel disease. The aim was to investigate if TWEAK may reflect disease activity in inflammatory bowel disease. Materials and methods: In this cohort study, 139 consecutive patients with newly diagnosed and previously untreated inflammatory bowel disease–95 with ulcerative colitis (UC) and 44 with Crohn’s disease (CD)–underwent colonoscopy. Disease activity was assessed by the Mayo score and the Mayo endoscopic score (MES) for UC, or the Simple Endoscopic Score (SES) for CD. Serum C-reactive protein (CRP) and fecal calprotectin were measured in IBD patients, as were plasma TWEAK levels in patients and 85 healthy subjects. Associations between TWEAK levels and disease activity markers were explored. Results: In the total IBD group, the median (interquartile range) TWEAK level was 430 pg/ml (109–6570), in UC 502 pg/ml (109–4547) and in CD patients 352 pg/ml (101–9179), respectively. Healthy subjects had a median (IQR) TWEAK of 307 pg/ml (63–3492). There were no significant differences in TWEAK levels between the total IBD group and healthy control subjects, nor between UC and CD, or between UC/CD and healthy subjects. Furthermore, we found no significant associations between Mayo scores, MES-UC, SES-CD, CRP, and fecal calprotectin with plasma TWEAK levels. Conclusions: Plasma TWEAK levels do not reflect disease activity or the grade of inflammation in patients with newly diagnosed inflammatory bowel disease. NCT01551563.

KW - biomarker

KW - Crohn’s disease

KW - Inflammatory bowel disease

KW - TWEAK

KW - ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85007453673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007453673&partnerID=8YFLogxK

U2 - 10.1080/00365521.2016.1273382

DO - 10.1080/00365521.2016.1273382

M3 - Article

VL - 52

SP - 420

EP - 424

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 4

ER -